CAR T-cell Therapy
Adoptive Cell Transfer + Immunotherapy for Melanoma
This trial is studying three different combinations of treatment as compared to treatment with T cells and high dose IL-2 alone in order to find which combination is the most effective in treating patients with melanoma.
Popular Filters
Trials for NSCLC Patients
PARP Inhibitor
Veliparib + Chemotherapy for Advanced Cancer
This trial is studying the side effects and best dose of veliparib when given with paclitaxel and carboplatin to treat patients with solid tumors that have spread or cannot be removed by surgery and have liver or kidney dysfunction.
MEK Inhibitor
AZD6244 + Chemotherapy for Advanced Cancer
This study is evaluating whether a combination of AZD6244 given orally twice a day with standard doses of selected chemotherapies will be safe and tolerable for cancer patients with advanced solid tumors. The highest tolerated dose of AZD6244 in combination with selected chemotherapies will be evaluated
Tyrosine Kinase Inhibitor
Entrectinib for Solid Tumors
This trial is testing a new drug, entrectinib, for patients with different types of solid tumors that have a gene fusion. Patients will be assigned to different groups depending on their tumor type and gene fusion.
Cancer Vaccine
Vaccine + Pembrolizumab for Cancer
This trial studies a combination of a special vaccine and pembrolizumab to treat patients with advanced solid tumors that haven't responded to other treatments. The vaccine helps the immune system recognize and attack cancer cells, while pembrolizumab boosts the immune system's ability to fight the cancer. Pembrolizumab has shown effectiveness in patients who have already received other treatments, with better outcomes and fewer side effects compared to some standard treatments.
Trials for Non-Small Cell Lung Cancer Patients
PARP Inhibitor
Veliparib + Chemotherapy for Advanced Cancer
This trial is studying the side effects and best dose of veliparib when given with paclitaxel and carboplatin to treat patients with solid tumors that have spread or cannot be removed by surgery and have liver or kidney dysfunction.
MEK Inhibitor
AZD6244 + Chemotherapy for Advanced Cancer
This study is evaluating whether a combination of AZD6244 given orally twice a day with standard doses of selected chemotherapies will be safe and tolerable for cancer patients with advanced solid tumors. The highest tolerated dose of AZD6244 in combination with selected chemotherapies will be evaluated
Tyrosine Kinase Inhibitor
Entrectinib for Solid Tumors
This trial is testing a new drug, entrectinib, for patients with different types of solid tumors that have a gene fusion. Patients will be assigned to different groups depending on their tumor type and gene fusion.
Cancer Vaccine
Vaccine + Pembrolizumab for Cancer
This trial studies a combination of a special vaccine and pembrolizumab to treat patients with advanced solid tumors that haven't responded to other treatments. The vaccine helps the immune system recognize and attack cancer cells, while pembrolizumab boosts the immune system's ability to fight the cancer. Pembrolizumab has shown effectiveness in patients who have already received other treatments, with better outcomes and fewer side effects compared to some standard treatments.
Trials for Metastatic Patients
Hu3F8 PET Imaging for Brain Cancer
This trial is studying how a special protein called Hu3F8 moves through the body and targets tumors. Hu3F8 is designed to attach to tumor cells, helping the immune system recognize and destroy them. The study focuses on patients with tumors to see how well this protein works in attacking cancer cells.
Cancer Vaccine
WDVAX Vaccine for Melanoma
This trial is looking at a new vaccine for melanoma, which is still being studied. The goal is to find out if the vaccine is safe and effective, as well as the appropriate dose. The vaccine contains the patient's own tumor cells, which have been killed and combined with other proteins.
Radiation Therapy
IMRT vs Proton Radiation Therapy for Sinonasal Cancer
This trial will test whether IMRT or proton radiation therapy improves local control rates and lowers toxicity compared to conventional radiation therapy in the treatment of locally advanced sinonasal malignancy.
PARP Inhibitor
Veliparib + Chemotherapy for Advanced Cancer
This trial is studying the side effects and best dose of veliparib when given with paclitaxel and carboplatin to treat patients with solid tumors that have spread or cannot be removed by surgery and have liver or kidney dysfunction.
Trials for BRAF Positive Patients
Kinase Inhibitor
Trametinib + Ceritinib for Melanoma
This trial is testing a new combination therapy for melanoma that has progressed despite other treatments. The goal is to see if this new combination is more effective than current treatments and has fewer side effects.
Kinase Inhibitor
LXH254 Combinations for Melanoma
This trial is testing a new medication called LXH254, used in combination with other treatments, for people with a type of skin cancer that can't be removed by surgery and has spread. These patients have already tried other treatments. LXH254 works by blocking signals in the cancer cells to slow or stop their growth.
Trials for PD-L1 Positive Patients
Kinase Inhibitor
Trametinib + Ceritinib for Melanoma
This trial is testing a new combination therapy for melanoma that has progressed despite other treatments. The goal is to see if this new combination is more effective than current treatments and has fewer side effects.
Procedure
ENB003 + Pembrolizumab for Cancer
This trial is testing a new cancer drug, ENB003, to see if it is safe and effective. The study will first test the drug on a small group of people to see what doses are safe. Then the study will be expanded to include more people with different types of cancer.
Monoclonal Antibodies
GEN1042 for Advanced Cancers
This trial is testing a new drug called GEN1042 to see if it can help treat advanced cancer. It focuses on patients whose cancer has spread or is hard to treat. The goal is to find out if GEN1042 can safely reduce or stop tumor growth.
Phase 3 Trials
Radiation
IGIMRT Dosing Schedules for Cancer Spread to Bone/Spine
This trial is studying two ways of giving high-dose radiation for treatment of cancer that has spread to bone, the spine, soft tissue, or lymph nodes. One way is 27 Gy in three fractions (3 days) and the other is 24 Gy in one fraction (1 day).
Checkpoint Inhibitor
Pembrolizumab for High-risk Stage II Melanoma
This trial will evaluate the safety and efficacy of pembrolizumab compared to placebo in participants with surgically resected high-risk Stage II melanoma. The primary hypothesis is that pembrolizumab increases recurrence-free survival.
Checkpoint Inhibitor
Relatlimab + Nivolumab for Advanced Melanoma
This trial is testing if using two medications together (relatlimab and nivolumab) is better than using just one (nivolumab) for treating a type of skin cancer that can't be removed by surgery or has spread. The drugs help the immune system to better recognize and attack cancer cells.
Nivolumab for Melanoma Prevention
This trial is testing if nivolumab can help prevent melanoma from returning in patients who have had their cancer surgically removed but are at high risk for it coming back. Nivolumab boosts the immune system to fight any remaining cancer cells. Nivolumab is used for the treatment of malignant melanoma and has shown promising anticancer activity in various cancers.
Kinase Inhibitor
Triple Drug Therapy for Advanced Melanoma
This trial is testing a combination of three drugs to treat advanced skin cancer in patients with a specific genetic mutation. One drug helps the immune system fight cancer, while the other two stop cancer cells from growing. The study aims to see if this combination is safe and effective.
Trials With No Placebo
Hu3F8 PET Imaging for Brain Cancer
This trial is studying how a special protein called Hu3F8 moves through the body and targets tumors. Hu3F8 is designed to attach to tumor cells, helping the immune system recognize and destroy them. The study focuses on patients with tumors to see how well this protein works in attacking cancer cells.
Cancer Vaccine
WDVAX Vaccine for Melanoma
This trial is looking at a new vaccine for melanoma, which is still being studied. The goal is to find out if the vaccine is safe and effective, as well as the appropriate dose. The vaccine contains the patient's own tumor cells, which have been killed and combined with other proteins.
Radiation Therapy
IMRT vs Proton Radiation Therapy for Sinonasal Cancer
This trial will test whether IMRT or proton radiation therapy improves local control rates and lowers toxicity compared to conventional radiation therapy in the treatment of locally advanced sinonasal malignancy.
PARP Inhibitor
Veliparib + Chemotherapy for Advanced Cancer
This trial is studying the side effects and best dose of veliparib when given with paclitaxel and carboplatin to treat patients with solid tumors that have spread or cannot be removed by surgery and have liver or kidney dysfunction.
View More Related Trials
Frequently Asked Questions
Introduction to melanoma
What are the top hospitals conducting melanoma research?
When it comes to advancing the treatment options for melanoma, several top hospitals in the United States are leading the way. Memorial Sloan Kettering Cancer Center, situated in New york City, is at the forefront of melanoma research with nine active clinical trials and an astonishing 115 completed trials dedicated to this aggressive form of skin cancer. Since recording their first melanoma trial in 1991, Memorial Sloan Kettering has been instrumental in pushing boundaries and improving outcomes for patients.
In Boston, both Massachusetts General Hospital and Dana Farber Cancer Institute are making significant contributions to melanoma research as well. Massachusetts General Hospital currently has seven ongoing clinical trials focused on melanoma while having accumulated a notable history of 86 previous studies since their first recorded trial back in 2003. Meanwhile, at Dana Farber Cancer Institute—another prominent medical institution within Boston's vibrant healthcare community—researchers are actively engaged in six clinical trials targeting melanoma after having conducted an impressive total of 64 such investigations since initiating their earliest recorded trial in 2004.
Further westward lies UPMC Hillman Cancer Center located in Pittsburgh—a formidable presence within the realm of melanoma research. With seven active clinical trials and a cumulative tally of 38 past investigations since they began exploring this field through their inaugural trial back in 2009, UPMC Hillman is committed to finding innovative solutions for patients facing this challenging diagnosis.
Lastly but certainly not least is MD Anderson Cancer Center based out of Houston—a renowned institution that has achieved breakthroughs across various cancers including melanoma. Currently conducting six active clinical trials pertaining to this specific malignancy while boasting a remarkable record of completing71 prior studies ever since embarking upon its initial investigation into treating melanoma backin1999,
These prestigious hospitals demonstrate exemplary dedication towards understanding and combating one of the deadliest formsof skin cancer- melonama.Their tireless effortsin pioneering treatmentsand conducting rigorousclinicaltrialsunderscore the necessity for continued research and collaboration. Through their collective achievements, they offer hope to countless patients while forging a path towards improved outcomes in the fight against melanoma
Which are the best cities for melanoma clinical trials?
When it comes to melanoma clinical trials, several cities are at the forefront of groundbreaking research. New york leads with 44 active trials focusing on Pembrolizumab, Botensilimab, PF-07799933, and other promising treatments. Boston follows closely behind with 36 trials investigating Pembrolizumab, DKY709, Botensilimab, among others. Los Angeles also emerges as a prominent location for melanoma clinical trials with 34 ongoing studies centered around Pembrolizumab, LXH254, Botensilimab. These cities offer individuals battling melanoma access to cutting-edge research that may pave the way for improved treatment options and potential breakthroughs in care.
Which are the top treatments for melanoma being explored in clinical trials?
Melanoma, a formidable foe in the world of cancer, spurs relentless research and development efforts. Prominent among the top treatments being explored in clinical trials are pembrolizumab and nivolumab. Pembrolizumab leads with seven active trials and an impressive history of 181 all-time melanoma trials since its inception in 2011. Nivolumab closely follows suit, exhibiting promising potential with four active studies and a noteworthy record of 165 all-time melanoma trials starting from 2010. Additionally, atezolizumab emerges as another contender for effective treatment, currently under investigation in two ongoing clinical trials alongside its involvement in 23 previous melanoma studies dating back to its introduction in 2012. As researchers push onward to uncover breakthroughs against this aggressive form of skin cancer, these innovative therapies offer renewed hope on the horizon.
What are the most recent clinical trials for melanoma?
Recent clinical trials for melanoma have introduced promising advancements in treatment options. One such trial focuses on a combination therapy, aiming to determine its effectiveness and safety in patients with melanoma. Another study is investigating the potential benefits of DP CD8 TIL, which could offer new therapeutic possibilities. Additionally, researchers are exploring the efficacy of HFB200603 as a monotherapy for melanoma. These clinical trials mark significant progress towards improving outcomes and quality of life for individuals battling this challenging disease.
What melanoma clinical trials were recently completed?
Numerous clinical trials for melanoma have been recently completed, showcasing the continuous efforts to advance treatment options. Among these trials are the completion of a study on PRT1419 by Prelude Therapeutics in August 2021, and the conclusion of Bayer's trial on BAY2666605 in April 2021. Additionally, Hoffmann-La Roche wrapped up their investigation into RO7293583 in October 2020, while Cantargia AB finished their CAN04 trial in September 2020. These recent milestones signify progress towards finding effective therapies for melanoma patients and inspire hope for improved outcomes in the future.